When patients need treatment for certain diseases, such as cancer, it’s not always immediately apparent which therapies they’ll respond to best. Branford-based IsoPlexis has developed a technology called single-cell proteomics—the protein equivalent of genomics—that helps doctors better predict disease progression and develop more effective treatments. Featured in dozens of peer-reviewed scientific publications and with versatility demonstrated across a wide range of research areas, the company’s technology isolates single immune cells and analyzes the proteins they secrete. Once doctors understand how various illnesses act at the single-cell level, they can better predict how patients will respond to existing therapies or even create new treatments.
Founded in 2013
- First investment: 2014
- First investment amount: $300,000
- Total invested: $7.6 million
- Leverage: $300 million
- Team lead: Daniel Wagner
In 2021, Mackay took the company public, raising $125 million in an IPO. IsoPlexis said it would use the funds to build out its commercial team and further advance on its path to becoming a major player in the precision medicine industry.
On December 21, 2022, IsoPlexis and Berkeley Lights, a life sciences tools company, announced that Berkeley Lights would acquire IsoPlexis in an all-stock transaction. The combined company will be named PhenomeX.